Charles River Laboratories International (CRL) Competitors

$302.24 +4.24 (+1.42%)

Closing price 03:59 PM Eastern

Extended Trading

$301.92 -0.32 (-0.11%)

As of 07:30 PM Eastern

CRL vs. ICLR, TECH, A, IQV, and RVTY

Should you buy Charles River Laboratories International stock or one of its competitors? Charles River Laboratories International's main competitors and comparable companies include Icon (ICLR), Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), and Revvity (RVTY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Charles River Laboratories International compare to Icon?

Charles River Laboratories International (NYSE:CRL) and Icon (NASDAQ:ICLR) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Charles River Laboratories International currently has a consensus target price of $300.11, suggesting a potential upside of 0.83%. Icon has a consensus target price of $172.40, suggesting a potential upside of 4.80%. Given Icon's higher probable upside, analysts plainly believe Icon is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88
Icon	2 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.39

Icon has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.54	-$144.34M	-$4.85	N/A
Icon	$8.25B	1.53	$229.34M	$4.26	38.62

In the previous week, Charles River Laboratories International had 21 more articles in the media than Icon. MarketBeat recorded 23 mentions for Charles River Laboratories International and 2 mentions for Icon. Charles River Laboratories International's average media sentiment score of 0.73 beat Icon's score of 0.67 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Icon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 95.6% of Icon shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 44.0% of Icon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Icon has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

Icon has a net margin of 3.99% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Icon	3.99%	8.02%	4.56%

Summary

Charles River Laboratories International beats Icon on 10 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to Bio-Techne?

Charles River Laboratories International (NYSE:CRL) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Bio-Techne has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.54	-$144.34M	-$4.85	N/A
Bio-Techne	$1.22B	9.35	$181.86M	$1.15	63.00

In the previous week, Charles River Laboratories International had 18 more articles in the media than Bio-Techne. MarketBeat recorded 23 mentions for Charles River Laboratories International and 5 mentions for Bio-Techne. Charles River Laboratories International's average media sentiment score of 0.73 beat Bio-Techne's score of 0.64 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Charles River Laboratories International has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Charles River Laboratories International currently has a consensus target price of $300.11, suggesting a potential upside of 0.83%. Bio-Techne has a consensus target price of $68.92, suggesting a potential downside of 4.87%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, equities research analysts plainly believe Charles River Laboratories International is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bio-Techne has a net margin of 14.97% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Bio-Techne	14.97%	13.23%	10.61%

Summary

Charles River Laboratories International beats Bio-Techne on 9 of the 16 factors compared between the two stocks.

How does Charles River Laboratories International compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	6.82	$1.30B	$5.08	33.09
Charles River Laboratories International	$4.02B	3.54	-$144.34M	-$4.85	N/A

In the previous week, Charles River Laboratories International had 17 more articles in the media than Agilent Technologies. MarketBeat recorded 23 mentions for Charles River Laboratories International and 6 mentions for Agilent Technologies. Charles River Laboratories International's average media sentiment score of 0.73 beat Agilent Technologies' score of 0.28 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Charles River Laboratories International	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has a net margin of 19.53% compared to Charles River Laboratories International's net margin of -5.96%. Agilent Technologies' return on equity of 24.45% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.53%	24.45%	13.09%
Charles River Laboratories International	-5.96%	15.75%	6.51%

Agilent Technologies has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Agilent Technologies currently has a consensus target price of $171.82, indicating a potential upside of 2.23%. Charles River Laboratories International has a consensus target price of $300.11, indicating a potential upside of 0.83%. Given Agilent Technologies' higher probable upside, equities analysts clearly believe Agilent Technologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.74
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88

98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Agilent Technologies beats Charles River Laboratories International on 10 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to IQVIA?

IQVIA (NYSE:IQV) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

89.6% of IQVIA shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IQVIA has a net margin of 8.10% compared to Charles River Laboratories International's net margin of -5.96%. IQVIA's return on equity of 30.25% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Charles River Laboratories International	-5.96%	15.75%	6.51%

IQVIA has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.61	$1.36B	$8.06	32.13
Charles River Laboratories International	$4.02B	3.54	-$144.34M	-$4.85	N/A

In the previous week, Charles River Laboratories International had 13 more articles in the media than IQVIA. MarketBeat recorded 23 mentions for Charles River Laboratories International and 10 mentions for IQVIA. Charles River Laboratories International's average media sentiment score of 0.73 beat IQVIA's score of 0.43 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	2 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Charles River Laboratories International	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA currently has a consensus price target of $274.31, indicating a potential upside of 5.92%. Charles River Laboratories International has a consensus price target of $300.11, indicating a potential upside of 0.83%. Given IQVIA's stronger consensus rating and higher possible upside, research analysts plainly believe IQVIA is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

IQVIA beats Charles River Laboratories International on 10 of the 15 factors compared between the two stocks.

How does Charles River Laboratories International compare to Revvity?

Charles River Laboratories International (NYSE:CRL) and Revvity (NYSE:RVTY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Revvity has a net margin of 8.16% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Revvity	8.16%	8.34%	5.01%

Charles River Laboratories International presently has a consensus price target of $300.11, indicating a potential upside of 0.83%. Revvity has a consensus price target of $120.50, indicating a potential downside of 20.87%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, equities research analysts plainly believe Charles River Laboratories International is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88
Revvity	0 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.26

In the previous week, Charles River Laboratories International had 12 more articles in the media than Revvity. MarketBeat recorded 23 mentions for Charles River Laboratories International and 11 mentions for Revvity. Charles River Laboratories International's average media sentiment score of 0.73 beat Revvity's score of 0.42 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revvity has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.54	-$144.34M	-$4.85	N/A
Revvity	$2.86B	5.95	$241.20M	$2.10	72.52

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Revvity has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Summary

Charles River Laboratories International beats Revvity on 12 of the 17 factors compared between the two stocks.

Get Charles River Laboratories International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRL vs. The Competition

Export

Metric	Charles River Laboratories International	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$14.43B	$10.57B	$7.20B	$22.96B
Dividend Yield	N/A	1.44%	2.53%	3.72%
P/E Ratio	-62.32	32.42	274.76	28.61
Price / Sales	3.61	503.96	632.15	94.35
Price / Cash	13.68	27.20	76.82	36.47
Price / Book	4.69	6.49	11.21	4.72
Net Income	-$144.34M	$56.67B	$3.50B	$1.07B
7 Day Performance	4.11%	-1.09%	-0.84%	0.35%
1 Month Performance	8.58%	8.84%	-5.42%	-3.80%
1 Year Performance	75.62%	28.78%	4.38%	6.48%

Charles River Laboratories International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRL Charles River Laboratories International	2.6132 of 5 stars	$302.24 +1.4%	$300.11 -0.7%	+71.5%	$14.43B	$4.00B	N/A	19,700	Insider Trade Analyst Revision
ICLR Icon	3.1759 of 5 stars	$164.08 +1.5%	$172.40 +5.1%	-11.8%	$12.38B	$8.25B	38.52	40,100	News Coverage Analyst Upgrade
TECH Bio-Techne	2.8256 of 5 stars	$72.53 +0.1%	$68.92 -5.0%	+19.6%	$11.36B	$1.22B	63.07	3,000	News Coverage
A Agilent Technologies	4.4589 of 5 stars	$169.07 -0.2%	$171.82 +1.6%	+19.4%	$47.74B	$6.95B	33.28	18,100	Ex-Dividend Analyst Forecast
IQV IQVIA	4.1249 of 5 stars	$258.56 -0.5%	$274.31 +6.1%	+29.1%	$42.79B	$16.31B	32.08	93,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CRL) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Summary

How does Charles River Laboratories International compare to IQVIA?

Summary

How does Charles River Laboratories International compare to Revvity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Do analysts recommend CRL or ICLR?

Which has higher valuation and earnings, CRL or ICLR?

Does the media favor CRL or ICLR?

Do institutionals & insiders have more ownership in CRL or ICLR?

Which has more volatility and risk, CRL or ICLR?

Is CRL or ICLR more profitable?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Which has better valuation & earnings, CRL or TECH?

Does the media favor CRL or TECH?

Which has more risk and volatility, CRL or TECH?

Do analysts prefer CRL or TECH?

Do insiders and institutionals have more ownership in CRL or TECH?

Is CRL or TECH more profitable?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Which has stronger earnings & valuation, A or CRL?

Does the media refer more to A or CRL?

Is A or CRL more profitable?

Which has more volatility and risk, A or CRL?

Do analysts recommend A or CRL?

Do insiders and institutionals believe in A or CRL?

Summary

How does Charles River Laboratories International compare to IQVIA?

Do insiders and institutionals hold more shares of IQV or CRL?

Is IQV or CRL more profitable?

Which has more risk and volatility, IQV or CRL?

Which has preferable valuation & earnings, IQV or CRL?

Does the media prefer IQV or CRL?

Do analysts recommend IQV or CRL?

Summary

How does Charles River Laboratories International compare to Revvity?

Is CRL or RVTY more profitable?

Do analysts rate CRL or RVTY?

Does the media favor CRL or RVTY?

Which has higher earnings and valuation, CRL or RVTY?

Do institutionals and insiders hold more shares of CRL or RVTY?

Which has more volatility and risk, CRL or RVTY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools